Literature DB >> 20944101

Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells.

R F Williams1, T L Sims, L Tracey, A L Myers, C Y C Ng, H Poppleton, A C Nathwani, A M Davidoff.   

Abstract

BACKGROUND: The vascular niche necessary for cancer stem cell maintenance is a potential target for cancer therapy.
MATERIALS AND METHODS: Human glioma xenografts were treated with IFN-β delivered systemically via a liver-targeted, adeno-associated viral vector. The vascular niche was examined with immunofluorescence for glioma stem cells, endothelial cells, and perivascular cells.
RESULTS: Although IFN-β was not directly toxic to glioma stem cells in vitro, IFN-β decreased tumor size and the number of stem cells recovered in both heterotopic and orthotopic models. Treatment with IFN-β increased perivascular cells investing the tumor vasculature (6-fold) distancing stem cells from endothelial cells. Additionally, vascular smooth muscle cells co-cultured between stem cells and endothelial cells decreased stem cell recovery.
CONCLUSION: Continuous delivery of IFN-β decreased the number of stem cells in glioma xenografts by disrupting the vascular niche through an increase in perivascular cells, which created a barrier between the glioma stem cells and the endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944101

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Cancer stem cells and drug resistance: the potential of nanomedicine.

Authors:  Serguei Vinogradov; Xin Wei
Journal:  Nanomedicine (Lond)       Date:  2012-04       Impact factor: 5.307

2.  Continuous local delivery of interferon-β stabilizes tumor vasculature in an orthotopic glioblastoma xenograft resection model.

Authors:  Jason W Denbo; Regan F Williams; W Shannon Orr; Thomas L Sims; Catherine Y Ng; Junfang Zhou; Yunyu Spence; Christopher L Morton; Amit C Nathwani; Christopher Duntsch; Lawrence M Pfeffer; Andrew M Davidoff
Journal:  Surgery       Date:  2011-09       Impact factor: 3.982

Review 3.  Targeting glioma stem cells: a novel framework for brain tumors.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Cancer Sci       Date:  2011-09-16       Impact factor: 6.716

Review 4.  Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.

Authors:  Wei Zhou; Zheng Jiang; Xingang Li; Yangyang Xu; Zhenyu Shao
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

Review 5.  Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.

Authors:  Gina Li; Nicolas Bonamici; Mahua Dey; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Expert Opin Drug Deliv       Date:  2017-09-18       Impact factor: 6.648

6.  CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma.

Authors:  Stuart J Smith; Hanna Tilly; Jennifer H Ward; Donald C Macarthur; James Lowe; Beth Coyle; Richard G Grundy
Journal:  Acta Neuropathol       Date:  2012-02-07       Impact factor: 17.088

7.  No role of IFITM3 in brain tumor formation in vivo.

Authors:  Nevenka Dudvarski Stankovic; Nicola Hoppmann; Marcin Teodorczyk; Ella L Kim; Matthias Bros; Alf Giese; Frauke Zipp; Mirko H H Schmidt
Journal:  Oncotarget       Date:  2016-12-27

Review 8.  Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting.

Authors:  Binbin Li; Qinghua Li; Jingxin Mo; Honglian Dai
Journal:  Front Pharmacol       Date:  2017-02-14       Impact factor: 5.810

9.  Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.

Authors:  Fabian Wolpert; Caroline Happold; Guido Reifenberger; Ana-Maria Florea; René Deenen; Patrick Roth; Marian Christoph Neidert; Katrin Lamszus; Manfred Westphal; Michael Weller; Günter Eisele
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

10.  Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.

Authors:  Olga V Matveeva; Zong S Guo; Svetlana A Shabalina; Peter M Chumakov
Journal:  Mol Ther Oncolytics       Date:  2015-07-22       Impact factor: 7.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.